PARP inhibitors and platinum chemotherapy expand blood stem cell clones linked to leukemia
PARP inhibitors and platinum chemotherapy expand blood stem cell clones that carry leukemia-associated mutations. Inherited defects in homologous recombination limit that expansion. The observation is reported in a Nature Genetics paper; the summary provides no cohort size or institutional information, and the full text requires a subscription. The authors note that therapy-related leukemia risk may hinge on the interaction of treatment history with inherited genetics.
Oncologists, and patients who receive PARP inhibitors or platinum chemotherapy, should weigh inherited genetics when assessing the risk of therapy-related leukemia. No clinical test is described.
Written by the Genomes desk from the primary source cited and linked above and checked against it. Research use only; not medical advice. Corrections: [email protected].